Biogen (BIIB) Net Income towards Common Stockholders (2009 - 2026)

Biogen (BIIB) has reported Net Income towards Common Stockholders for 18 consecutive years, with $319.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 32.85% year-over-year to $319.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 7.26% YoY), while the FY2025 annual figure was $1.3 billion, down 20.79% from the prior year.
• Net Income towards Common Stockholders came in at $319.5 million for Q1 2026 at Biogen, up from -$48.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $1.1 billion in Q3 2022, with the low at -$64.2 million in Q3 2023.
• Average Net Income towards Common Stockholders over 5 years is $437.3 million, with a median of $393.4 million recorded in 2024.
• Across the five-year window, Net Income towards Common Stockholders surged 948.37% in 2022 and plunged 118.34% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $559.0 million in 2022, then sank by 55.47% to $248.9 million in 2023, then increased by 7.15% to $266.7 million in 2024, then slumped by 118.34% to -$48.9 million in 2025, then surged by 753.37% to $319.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $319.5 million, -$48.9 million, and $466.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.